Intraperitoneal Chemotherapy from Armstrong to HIPEC: Challenges and Promise

Current Treatment Options in Oncology

Volumn 15, Issue 1, 2014, Pages 27-40

  Eskander, Ramez N ^a   Cripe, James ^b   Bristow, Robert E ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

Cytoreductive surgery; HIPEC; Intraperitoneal chemotherapy; Ovarian cancer

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GEMCITABINE; MITOMYCIN; MITOXANTRONE; OXALIPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE;

ABSCESS; ANASTOMOSIS LEAKAGE; ANEMIA; ARTICLE; BLEEDING; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CANCER THERAPY; CYTOREDUCTIVE SURGERY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSAGE FORM COMPARISON; DRUG TOLERABILITY; FALLOPIAN TUBE CANCER; FISTULA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HUMAN; HYPERTHERMIC THERAPY; INFECTION; INTRAOPERATIVE HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; LUNG EMBOLISM; METABOLIC DISORDER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; PLEURA EFFUSION; PROGRESSION FREE SURVIVAL; SYSTEMIC THERAPY; UTERINE TUBE TUMOR; VOMITING; WOUND DEHISCENCE; WOUND INFECTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II AS TOPIC; COMBINED MODALITY THERAPY; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; INFUSIONS, PARENTERAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; TREATMENT OUTCOME;

EID: 84894683152     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-013-0264-2     Document Type: Article

References (66)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
3. Bookman M. Trials with impact on clinical management: first line. Int J Gynecol Cancer. 2009;19 Suppl 2:S55-62.
4. Cannistra SA. Cancer of the ovary. N Engl J Med. 1993;329:1550-9.
5. Winter III WE, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:3621-7.
6. Helm CW, Bristow RE, Kusamura S, Baratti D, Deraco M. Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer. J Surg Oncol. 2008;98:283-90.
7. Tentes AA, Kakolyris S, Kyziridis D, Karamveri C. Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy in the treatment of advanced epithelial ovarian cancer. J Oncol. 2012;2012:358341
8. Rossi CR, Foletto M, Mocellin S, Pilati P, De SM, Deraco M, et al. Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis: phase I study. Cancer. 2002;94:492-9.
9. Markman M, Rowinsky E, Hakes T, Reichman B, Jones W, Lewis JL Jr, et al. Intraperitoneal administration of Taxol in the management of ovarian cancer. J Natl Cancer Inst Monogr. 1993:103-6.
10. Markman M, Rowinsky E, Hakes T, Reichman B, Jones W, Lewis Jr JL, et al. Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study. J Clin Oncol. 1992;10:1485-91.
11. Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel vs moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19:1001-7.
12. Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide vs intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335:1950-5.
13. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34-43.
14. Trimble EL, Alvarez RD. Intraperitoneal chemotherapy and the NCI clinical announcement. Gynecol Oncol. 2006;103(2 Suppl 1):S18-9.
15. Landrum LM, Java J, Mathews CA, Lanneau Jr GS, Copeland LJ, Armstrong DK, et al. Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol. 2013;130:12-8.
16. Sabbatini PJ, Hensley ML, et al. Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian,fallopian tube, and primary peritoneal cancer. Gynecol Oncol. 2012;125(3):621-4.
17. Nicoletto MO, Padrini R, Galeotti F, Ferrazzi E, Cartei G, Riddi F, et al. Pharmacokinetics of intraperitoneal hyperthermic perfusion with mitoxantrone in ovarian cancer. Cancer Chemother Pharmacol. 2000;45:457-62.
18. Ohno S, Siddik ZH, Kido Y, Zwelling LA, Bull JM. Thermal enhancement of drug uptake and DNA adducts as a possible mechanism for the effect of sequencing hyperthermia on cisplatin-induced cytotoxicity in L1210 cells. Cancer Chemother Pharmacol. 1994;34:302-6.
19. Vernon C. Hyperthermia in cancer growth regulation. Biotherapy. 1992;4:307-15.
20. Robins HI. Role of whole-body hyperthermia in the treatment of neoplastic disease: its current status and future prospects. Cancer Res. 1984;44(Suppl):4878s-83.
21. Shiu MH, Fortner JG. Intraperitoneal hyperthermic treatment of implanted peritoneal cancer in rats. Cancer Res. 1980;40:4081-4.
22. Larkin JM. A clinical investigation of total-body hyperthermia as cancer therapy. Cancer Res. 1979;39(6 Pt 2):2252-4.
23. Kowal CD, Bertino JR. Possible benefits of hyperthermia to chemotherapy. Cancer Res. 1979;39(6 Pt 2):2285-9.
24. Johnson RJ, Subjeck JR, Moreau DZ, Kowal H, Yakar D. Radiation and hyperthermia. Bull N Y Acad Med. 1979;55:1193-204.
25. Weisberger AS, Levine B, Storaasli JP. Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. JAMA. 1955;159:1704-7.
26. Jones RB, Myers CE, Guarino AM, Dedrick RL, Hubbard SM, DeVita VT. High volume intraperitoneal chemotherapy ("belly bath") for ovarian cancer. Pharmacologic basis and early results. Cancer Chemother Pharmacol. 1978;1:161-6.
27. Potter ME, Partridge EE, Shingleton HM, Soong SJ, Kim RY, Hatch KD, et al. Intraperitoneal chromic phosphate in ovarian cancer: risks and benefits. Gynecol Oncol. 1989;32:314-8.
28. Spratt JS, Adcock RA, Muskovin M, Sherrill W, McKeown J. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res. 1980;40:256-60.
29. Sugarbaker PH. Complete parietal and visceral peritonectomy of the pelvis for advanced primary and recurrent ovarian cancer. Cancer Treat Res. 1996;81:75-87.
30. Gori J, Castano R, Toziano M, Habich D, Staringer J, De Quiros DG, et al. Intraperitoneal hyperthermic chemotherapy in ovarian cancer. Int J Gynecol Cancer. 2005;15:233-9.
31. Cohen JD, Robins HI. Whole body hyperthermia and intraperitoneal carboplatin in residual ovarian cancer. Adv Exp Med Biol. 1990;267:197-202.
32. Steller MA, Egorin MJ, Trimble EL, Bartlett DL, Zuhowski EG, Alexander HR, et al. A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer. Cancer Chemother Pharmacol. 1999;43:106-14.
33. Hager ED, Dziambor H, Hohmann D, Muhe N, Strama H. Intraperitoneal hyperthermic perfusion chemotherapy of patients with chemotherapy-resistant peritoneal disseminated ovarian cancer. Int J Gynecol Cancer. 2001;11 Suppl 1:57-63.
34. Piso P, Dahlke MH, Loss M, Schlitt HJ. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer. World J Surg Oncol. 2004;2:21.
35. Ryu KS, Kim JH, Ko HS, Kim JW, Ahn WS, Park YG, et al. Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer. Gynecol Oncol. 2004;94:325-32.
36. Rufian S, Munoz-Casares FC, Briceno J, Diaz CJ, Rubio MJ, Ortega R, et al. Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer. J Surg Oncol. 2006;94:316-24.
37. Bae JH, Lee JM, Ryu KS, Lee YS, Park YG, Hur SY, et al. Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery. Gynecol Oncol. 2007;106:193-200.
38. Lentz SS, Miller BE, Kucera GL, Levine EA. Intraperitoneal hyperthermic chemotherapy using carboplatin: a phase I analysis in ovarian carcinoma. Gynecol Oncol. 2007;106:207-10.
39. Kusamura S, Dominique E, Baratti D, Younan R, Deraco M. Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy. J Surg Oncol. 2008;98:247-52.
40. Pavlov MJ, Kovacevic PA, Ceranic MS, Stamenkovic AB, Ivanovic AM, Kecmanovic DM. Cytoreductive surgery and modified heated intraoperative intraperitoneal chemotherapy (HIPEC) for advanced and recurrent ovarian cancer - 12-year single center experience. Eur J Surg Oncol. 2009;35:1186-91.
41. Bakrin N, Cotte E, Golfier F, Gilly FN, Freyer G, Helm W, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospective study of 246 patients. Ann Surg Oncol. 2012;19:4052-8.
42. Helm CW, Richard SD, Pan J, Bartlett D, Goodman MD, Hoefer R, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer: first report of the HYPER-O registry. Int J Gynecol Cancer. 2010;20:61-9.
43. Zanon C, Clara R, Chiappino I, Bortolini M, Cornaglia S, Simone P, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer. World J Surg. 2004;28:1040-5.
44. Cotte E, Glehen O, Mohamed F, Lamy F, Falandry C, Golfier F, et al. Cytoreductive surgery and intraperitoneal chemo-hyperthermia for chemo-resistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients. World J Surg. 2007;31:1813-20.
45. Raspagliesi F, Kusamura S, Campos Torres JC, de Souza GA, Ditto A, Zanaboni F, et al. Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: the experience of National Cancer Institute of Milan. Eur J Surg Oncol. 2006;32:671-5.
46. Yoshida Y, Sasaki H, Kurokawa T, Kawahara K, Shukunami K, Katayama K, et al. Efficacy of intraperitoneal continuous hyperthermic chemotherapy as consolidation therapy in patients with advanced epithelial ovarian cancer: a long-term follow-up. Oncol Rep. 2005;13:121-5.
47. Kim JH, Lee JM, Ryu KS, Lee YS, Park YG, Hur SY, et al. Consolidation hyperthermic intraperitoneal chemotherapy using paclitaxel in patients with epithelial ovarian cancer. J Surg Oncol. 2010;101:149-55.
48. Frenel JS, Leux C, Pouplin L, Ferron G, Berton Rigaud D, Bourbouloux E, et al. Oxaliplatin-based hyperthermic intraperitoneal chemotherapy in primary or recurrent epithelial ovarian cancer: a pilot study of 31 patients. J Surg Oncol. 2011;103:10-6.
49. Ansaloni L, Agnoletti V, Amadori A, Catena F, Cavaliere D, Coccolini F, et al. Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer. 2012;22:778-85.
50. Ceelen WP, Van Nieuwenhove Y, Van Belle S, Denys H, Pattyn P. Cytoreduction and hyperthermic intraperitoneal chemoperfusion in women with heavily pretreated recurrent ovarian cancer. Ann Surg Oncol. 2012;19:2352-9. A contemporary study exploring HIPEC in the recurrent setting. Despite multiple prior lines of therapy, HIPEC was deemed safe.
51. Deraco M, Kusamura S, Virzi S, Puccio F, Macri A, Famulari C, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial. Gynecol Oncol. 2011;122:215-20. One of the largest phase II studies exploring the efficacy and toxicity of HIPEC in ovarian cancer patients. This study illustrated the feasability of this approach in appropriately selected patietns, with acceptable oncologic outcomes.
52. Di Giorgio A, Naticchioni E, Biacchi D, Sibio S, Accarpio F, Rocco M, et al. Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer. 2008;113:315-25.
53. Fagotti A, Costantini B, Petrillo M, Vizzielli G, Fanfani F, Margariti PA, et al. Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: a case-control study on survival in patients with two year follow-up. Gynecol Oncol. 2012;127:502-5.
54. Fagotti A, Costantini B, Vizzielli G, Perelli F, Ercoli A, Gallotta V, et al. HIPEC in recurrent ovarian cancer patients: morbidity-related treatment and long-term analysis of clinical outcome. Gynecol Oncol. 2011;122:221-5. Contemporary article focusing on HIPEC related morbidity.
55. Lim MC, Kang S, Choi J, Song YJ, Park S, Seo SS, et al. Hyperthermic intraperitoneal chemotherapy after extensive cytoreductive surgery in patients with primary advanced epithelial ovarian cancer: interim analysis of a phase II study. Ann Surg Oncol. 2009;16:993-1000.
56. Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy vs systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737-43.
57. Markman M. Hyperthermic intraperitoneal chemotherapy in the management of ovarian cancer: a critical need for an evidence-based evaluation. Gynecol Oncol. 2009;113:4-5.
58. Ansaloni L, De Iaco P, Frigerio L. Re: "cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase II trial." Proposal of a clinical trial of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer, the CHORINE study. Gynecol Oncol. 2012;125:279-81.
59. Verwaal VJ, van Tinteren H, Ruth SV, Zoetmulder FA. Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. J Surg Oncol. 2004;85:61-7.
60. Schierl R, Novotna J, Piso P, Bohlandt A, Nowak D. Low surface contamination by cis/oxaliplatin during hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Surg Oncol. 2012;38:88-94.
61. Li G, Gu R, Wen X, Wei D, Ming X, Chen H. The effect of early enteral nutrition on hyperthermic intraoperative intraperitoneal chemotherapy-induced mucosal permeability following gastrectomy. J Parenter Enteral Nutr. 2012;36:213-8.
62. Kusamura S, Baratti D, Deraco M. Multidimensional analysis of the learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies. Ann Surg. 2012;255:348-56.
63. Duckworth KE, McQuellon RP, Russell GB, Cashwell CS, Shen P, Stewart JHt, et al. Patient rated outcomes and survivorship following cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CS + HIPEC). J Surg Oncol. 2012;15;106(4):376-80.
64. Parson EN, Lentz S, Russell G, Shen P, Levine EA, Stewart JH. Outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface dissemination from ovarian neoplasms. Am J Surg. 2011;202:481-6.
65. Konigsrainer I. Selection criteria for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer. World J Gastroenterol. 2011;17:4153-6.
66. Hill AR, McQuellon RP, Russell GB, Shen P, Stewart JH, Levine EA. Survival and quality of life following cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of colonic origin. Ann Surg Oncol. 2011;18:3673-9.